Atlas Trials

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

Clinical trial NCT06511570 · COMPLETED

Trial details

NCT number
NCT06511570
Sponsor
Acumen Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Alzheimer Disease
Start date
2024-06-25
Primary completion
2024-09-17
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.